GLAXF — GSK plc
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1131399 ·
United Kingdom
Last close
$24.00
Market Cap
$96.13B
52W High
$31.19
52W Low
$20.43
ADV30
1,007
Next earnings
2026-10-28
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 7,629,000,000 | 5,754,000,000 | 2,293,000,000 | 1,737,000,000 | 62,869,000,000 | 3,442,000,000 | 45,447,000,000 |
| Dec 2025 | 8,618,000,000 | 5,961,000,000 | 1,506,000,000 | 636,000,000 | 61,118,000,000 | 3,150,000,000 | 45,162,000,000 |
| Sep 2025 | 8,547,000,000 | 6,289,000,000 | 2,593,000,000 | 2,013,000,000 | 61,339,000,000 | 3,296,000,000 | 45,587,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$8,331,000,000
Investing CF
$-4,719,000,000
Financing CF
$-4,048,000,000
CapEx
$-3,000,000,000
Dividends Paid
$-2,666,000,000
Buybacks
$-1,203,000,000
EPS Diluted TTM
$1.04
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$11,464,000,000
Inventory
$6,282,000,000
Receivables
—
ST Investments
$1,000,000
EBIT TTM
$6,594,000,000
Pretax Income TTM
$5,904,000,000
Interest Exp TTM
$690,000,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$33,202,999,296
EBITDA
$10,817,999,872
Free Cash Flow
$3,482,625,024
Enterprise Value
$110,887,002,112
Total Cash
$3,105,999,872
Total Debt
$18,293,000,192
Shares Out
4,005,611,246
Trailing EPS
$1.60
Book Value
$5.95
ROE
33.4%
ROA
10.0%
Div Yield
3.82%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 32,667,000,000 | 8,338,000,000 | 5,716,000,000 | 61,118,000,000 | 45,162,000,000 | 16,377,000,000 | 7,741,000,000 |
| Dec 2024 | 31,376,000,000 | 5,542,000,000 | 2,575,000,000 | 59,463,000,000 | 46,377,000,000 | 13,671,000,000 | 6,554,000,000 |
| Dec 2023 | 30,328,000,000 | 7,345,000,000 | 4,928,000,000 | 59,005,000,000 | 46,210,000,000 | 13,347,000,000 | 6,768,000,000 |
| Dec 2022 | 29,324,000,000 | 6,729,000,000 | 14,956,000,000 | 60,146,000,000 | 50,050,000,000 | 10,598,000,000 | 7,403,000,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$2.20
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SNYNF | Sanofi | $96.05B | $80.17 | — |
| GSK | GSK plc | $96.48B | $48.17 | — |
| SNY | Sanofi | $98.79B | $41.23 | — |
| REGN | REGENERON PHARMACEUTICALS, INC. | $76.69B | $758.27 | — |
| NVO | NOVO NORDISK A S | $126.77B | $37.91 | — |
News headlines (Yahoo Finance, 1h cache)
GSK (LSE:GSK) The Latest Update Raises A Bigger Question
2026-09-30 11:13 · Yahoo
Hatteras Venture Partners Names Sir Andrew Witty as Chairman and Ned Sharpless, M.D., as Managing Director of Hatteras Discovery Innovation, Expanding Proven Investment Strategies
2026-09-30 11:00 · Yahoo
GSK vs. SNY: Which Europe-Based Pharma Stock Has More Potential?
2026-09-29 11:37 · Yahoo
GSK retains ‘buy’ rating at Jefferies as B7H3 cancer programme seen as underappreciated
2026-09-29 11:30 · Yahoo
Merck, Daiichi Withdraw FDA Filing for Lung Cancer Therapy
2026-09-28 15:23 · Yahoo
Berenberg Turns Bullish on GSK as its $750 Million Deal Adds to Pipeline Momentum
2026-09-24 23:08 · Yahoo
GSK Adds Another Cancer Drug in a $750 Million Deal. Is its Oncology Bet Getting Bigger?
2026-09-24 22:41 · Yahoo
GSK Bets on HUTCHMED to Expand its Multi-Billion-Dollar Oncology Opportunity
2026-09-24 20:59 · Yahoo
$3.3 Million in New Philanthropic Commitments for Good Jobs Western North Carolina from The Rockefeller Foundation, John M. Belk Endowment, and NC GSK Foundation
2026-09-24 11:00 · Yahoo
GSK Bets on Long-Acting Biologics and AI to Reshape Respiratory Care
2026-09-23 22:02 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.